Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients Heather Hampel, Jenny Panescu, Janet Lockman, et al. Cancer Res 2007;67:9603.
Updated version
Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/67/19/9603
Cited Articles
This article cites by 2 articles, 2 of which you can access for free at: http://cancerres.aacrjournals.org/content/67/19/9603.full.html#ref-list-1
Citing articles
This article has been cited by 4 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/67/19/9603.full.html#related-urls
E-mail alerts Reprints and Subscriptions Permissions
Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at
[email protected]. To request permission to re-use all or part of this article, contact the AACR Publications Department at
[email protected].
Downloaded from cancerres.aacrjournals.org on June 7, 2013. © 2007 American Association for Cancer Research.
Letters to the Editor
Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients
Heather Hampel Jenny Panescu Janet Lockman Kaisa Sotamaa Daniel Fix Ilene Comeras Jennifer LaJeunesse Hidewaki Nakagawa Judith A. Westman Thomas W. Prior Mark Clendenning Albert de la Chapelle Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
To the Editor: This correspondence is an addendum to our recent report (1) about the prevalence of Lynch syndrome among all newly diagnosed endometrial cancer patients. Two additional deleterious MSH6 gene mutations were found on completion of molecular analysis in the last 19 patients. In addition, RNA studies have allowed the reclassification of one of the presumptive missense mutations c.1304T>C (p.Leu435Pro) from the original report as a deleterious frameshift mutation. As a result, the prevalence of Lynch syndrome in our cohort of Columbus, OH area endometrial cancer patients has increased from 1.8% to 2.3% (95% confidence interval, 1.3–4.0%). This is an important update as many institutions and policy groups are considering whether to implement screening for Lynch syndrome among endometrial cancer patients. We reported 10 Lynch syndrome cases out of 543 patients with completed molecular analysis and a total of 564 patients on study. Two patients have since been removed from study for insufficient tumor material, leaving 562 patients on study. Molecular analysis has now been performed in the 19 patients who did not have testing completed at the time of publication. Two of the 19 patients were found to have nonsense mutations in MSH6. Case 18 is a Caucasian female with mixed endometrioid and clear cell carcinoma diagnosed at age 58 years whose family history meets the Bethesda guidelines (2). Her tumor was microsatellite instability (MSI) high, immunohistochemistry was absent for MSH6 only, and she was found to have a c.3768T>G (p.Tyr1256X) mutation. Case 1079 is an AfricanAmerican patient diagnosed with endometrioid carcinoma at age 51 years whose family history does not meet any published Lynch syndrome criteria. Her tumor failed MSI testing; however, immunohistochemistry staining indicated the absence only of MSH6 so sequencing of the MSH6 gene was performed. She was found to have a c. 220G>T (p.Gly74X) mutation. Finally, we reported that case 1493 was found to have a c.1304T>C (p.Leu435Pro) mutation in MSH6, which was a sequence change of unknown significance. Reverse transcription-PCR run on a gel clearly displays exon skipping. Sequencing of the patient’s cDNA verifies aberrant splicing causing skipping of exon 4 in MSH6. Overall, with these additions, 8 of the 13 (61.5%) cases were diagnosed at age 50 years or later, 8 did not meet any of the published family history criteria for the diagnosis of Lynch syndrome, and 2 would have been missed by MSI testing (1 negative and 1 failed).
www.aacrjournals.org
Wendy Frankel Department of Pathology, The Ohio State University, Columbus, Ohio Pamela Penzone David E. Cohn Larry Copeland Lynne Eaton Jeffrey Fowler Division of Gynecologic Oncology, The Ohio State University, Columbus, Ohio Janet Lombardi Patti Dunn Jeffrey Bell Gary Reid Central Ohio Gynecologic Oncology, Riverside Methodist Hospital, Columbus, Ohio George Lewandowski Luis Vaccarello Gynecologic Oncology and Pelvic Surgery Associates, Mount Carmel Health System, Columbus, Ohio
References 1. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810–7. 2. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261–8.
9603
I2007 American Association for Cancer Research. doi:10.1158/0008-5472.CAN-07-2308
Cancer Res 2007; 67: (19). October 1, 2007
Downloaded from cancerres.aacrjournals.org on June 7, 2013. © 2007 American Association for Cancer Research.
